Fourier Intelligence

Fourier Intelligence is a robotics company headquartered in Shanghai, China, founded in 2015. The company initially focused on rehabilitation robotics and wearable exoskeleton systems for clinical and home-use applications, developing products aimed at patients with motor impairments. In recent years, Fourier has expanded into general-purpose humanoid robotics with its GR series, shifting from medical devices toward broader commercial and industrial use cases. The company maintains its Shanghai headquarters and has participated in trade events including the World AI Conference, where it has showcased humanoid prototypes. Fourier's trajectory reflects a pattern seen across several Chinese robotics firms: a pivot from specialized therapeutic or assistive devices into the wider humanoid market as hardware costs have declined and interest in general-purpose manipulation platforms has grown. The company's rehabilitation background differentiates it from humanoid startups that lack a prior revenue-generating product line, though the commercial scale of the earlier medical business remains unclear from public disclosures.

Fourier's current humanoid portfolio includes two models: the GR-2 and the GR-3. The GR-2 is described as a full-body humanoid platform intended for general-purpose manipulation tasks. It follows the GR-1, which Fourier introduced in 2023 as a 1.65-meter, 55-kilogram bipedal platform with 40 degrees of freedom and a claimed payload of approximately 5 kilograms per arm. The GR-2 represents an iterative hardware revision with improvements in joint torque density and actuator design, though specific performance benchmarks remain limited in public documentation. The GR-3 is positioned as a humanoid care-bot, suggesting an application focus closer to Fourier's rehabilitation and assistive-technology origins. At the time of writing, Fourier has primarily demonstrated these platforms through controlled video footage and trade-show appearances. The company has not publicly disclosed production volumes, unit pricing, or commercial delivery timelines. Portfolio breadth should not be confused with commercial maturity across all listed models.

Fourier Intelligence's deployment relevance for enterprise buyers evaluating humanoid platforms centers on three factors: the company's existing commercial track record in rehabilitation robotics, the design continuity across its GR-series humanoid line, and the industrial-use-case alignment suggested by the GR-2's general-purpose positioning. Fourier's background in regulated medical devices implies experience with hardware quality systems and product safety processes, though it is not yet clear how much of that infrastructure transfers to general-purpose humanoid production. The absence of publicly confirmed customer deployments for the GR series means that buyers should treat Fourier's humanoid offerings as pre-commercial or early-pilot-stage platforms. Deployment relevance will remain provisional until the company discloses customer-confirmed pilots, operating hours, unit availability, after-sales support structures, and commercial pricing. Organizations with parallel interests in rehabilitation robotics and general-purpose manipulation may find Fourier's combined portfolio worth monitoring, but procurement decisions would benefit from direct engagement with the company regarding delivery commitments and field performance data.